Lord Abbett & CO. LLC增加了其联合治疗公司的持股，反映了这家生物技术公司的强劲季度表现。 Lord Abbett & CO. LLC increased its United Therapeutics holdings, reflecting strong quarterly performance by the biotech firm.

投资公司Abbett Lord & CO. LLC将其在联合治疗公司(UTHR)的股份增加了7.4%,现在拥有216 651股,价值7 640万美元。 Investment firm Lord Abbett & CO. LLC increased its holdings in United Therapeutics (UTHR) by 7.4%, now owning 216,651 shares worth $76.4 million. United Therapeutics 报告称，本季度表现强劲，每股收益为 6.19 美元，超出预期 0.09 美元。 United Therapeutics reported a strong quarter with EPS of $6.19, beating estimates by $0.09. 该生物技术公司的市场上限为133.1亿美元,P/E比率为13.02。 The biotech company has a market cap of $13.31 billion and a P/E ratio of 13.02. 企业拥有94.08%的股票,分析师拥有“机动购买”评级,目标价格为395.67美元。 Institutions own 94.08% of the stock, and analysts have a "Moderate Buy" rating with a target price of $395.67.